INmune Bio Inc (NASDAQ:INMB)
| 6.80 Delayed Data As of May 27 |  +0.47 / +7.42%Today’s Change | 4.63 Today|||52-Week Range 30.37 | -33.33% Year-to-Date |
Latest INMB News | Press Releases
| INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study May 25 / Zacks.com - Paid Partner Content | Biotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers Updates May 25 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 6.33 |
| Today’s open | 6.47 |
| Day’s range | 6.47 - 6.95 |
| Volume | 6,287 |
| Average volume (3 months) | 154,082 |
| Market cap | $132.1M |
Data as of 3:59pm ET, 05/27/2022
Growth & Valuation
| Earnings growth (last year) | -86.38% |
| Earnings growth (this year) | -5.91% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +1,558.12% |
| P/E ratio | NM |
| Price/Sales | 909.01 |
| Price/Book | 1.64 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CRMDCorMedix Inc | -0.08 | -2.52% |
| URGNUrogen Pharma Ltd | +0.27 | +5.22% |
| TCRTAlaunos Therapeutics... | +0.05 | +10.73% |
| SELBSelecta Biosciences ... | +0.07 | +9.96% |
Data as of 4:00pm ET, 05/27/2022
Financials
| Next reporting date | August 15, 2022 |
| EPS forecast (this quarter) | -$0.49 |
| Annual revenue (last year) | $181.0K |
| Annual profit (last year) | -$30.3M |
| Net profit margin | -16,762.43% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Boca Raton, Florida |
Forecasts
